| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Rallybio Corp | Chief Medical Officer | Option (Right to Buy) | 180,000 | $126,000 | $0.7000 | 14 Feb 2025 | Direct |
| MBX Biosciences, Inc. | Director | Stock option (right to buy) | 16,000 | 05 Jun 2025 | Direct | ||
| REATA PHARMACEUTICALS INC | Director | Class A common stock | 0 | $172.03 | 26 Sep 2023 | Direct | |
| REATA PHARMACEUTICALS INC | Director | Stock Option (right to buy) | 0 | 26 Sep 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | 05 Jun 2025 | 1 | $0 | 4 | Director | 06 Jun 2025, 08:03 |
| RLYB | Rallybio Corp | 14 Feb 2025 | 1 | $0 | 4 | Chief Medical Officer | 19 Feb 2025, 19:29 |
| MBX | MBX Biosciences, Inc. | 12 Sep 2024 | 1 | $0 | 4 | Director | 13 Sep 2024, 17:17 |
| MBX | MBX Biosciences, Inc. | 12 Sep 2024 | 0 | $0 | 3 | Director | 12 Sep 2024, 19:17 |
| RLYB | Rallybio Corp | 15 Feb 2024 | 1 | $0 | 4 | Chief Medical Officer | 16 Feb 2024, 18:18 |
| RETA | REATA PHARMACEUTICALS INC | 26 Sep 2023 | 6 | $0 | 4 | Director | 26 Sep 2023, 16:30 |
| RETA | REATA PHARMACEUTICALS INC | 07 Jun 2023 | 4 | +$222,428 | 4 | Director | 09 Jun 2023, 16:38 |
| RLYB | Rallybio Corp | 06 Feb 2023 | 1 | $0 | 4 | Chief Medical Officer | 06 Feb 2023, 16:40 |
| RETA | REATA PHARMACEUTICALS INC | 11 Jul 2022 | 6 | +$316,852 | 4 | Director | 12 Jul 2022, 16:26 |
| RETA | REATA PHARMACEUTICALS INC | 11 Jul 2022 | 0 | $0 | 3 | Director | 11 Jul 2022, 16:40 |
| RLYB | Rallybio Corp | 07 Feb 2022 | 1 | $0 | 4 | Chief Medical Officer | 09 Feb 2022, 18:37 |
| RLYB | Rallybio Corp | 29 Jul 2021 | 0 | $0 | 3 | Chief Medical Officer | 29 Jul 2021, 19:36 |